• AAPL 180.96
  • AMZN 123.43
  • BTC-USD 25809.8535
  • ETH-USD 1750.6583
  • EURUSD 1.0749
  • TSLA 244.4
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. NVSEF.US

Novartis AG (NVSEF PINK) stock market data APIs

$100.81 0(0%) as of June 9, 2023

Novartis AG Financial Data Overview

100.81
100.81
-
100.81
100.81
70.0308-106.5
213 678 M
30.8287
2 120 M
52 222 M
1.71
0.0349
0.4727
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NVSEF',
Type: 'Common Stock',
Name: 'Novartis AG',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000KSBX82',
ISIN: 'CH0012005267',
CUSIP: NULL,
CIK: '1114448',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers-General',
GicSector: NULL,
GicGroup: NULL,
GicIndustry: NULL,
GicSubIndustry: NULL,
HomeCategory: NULL,
IsDelisted: false,
}

Novartis AG Fundamental Data is available in our Financial Data APIs

  • Net Revenue 52 222 M
  • EBITDA 18 593 M
  • Earnings Per Share 3.27
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Novartis AG Earnings via APIs

  • Latest Release 2023-04-25
  • EPS/Forecast 1.53

Get Novartis AG End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Novartis AG latest news via APIs

Novartis (NVS) Sandoz Presents Standalone Growth Strategy

Novartis’ NVS generic unit, Sandoz, outlined its growth strategy in New York City as a standalone company following the proposed 100% spin-off from Novartis. Sandoz reported sales of $9.1 billion i...

FDA Accepts Vertex (VRTX), CRISPR's BLA Filings for Exa-Cel

Vertex Pharmaceuticals VRTX and CRISPR Therapeutics CRSP announced that the FDA has accepted their biologics license applications (“BLAs”) for exagamglogene autotemcel (“exa-cel”) to treat sic...
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com
We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy.